Binding of Amyloid Beta Peptide to Beta2 Adrenergic Receptor Induces PKA-dependent AMPA Receptor Hyperactivity

Overview

Journal FASEB J

Specialties Biology
Physiology

Date 2010 Apr 17

PMID 20395454

Citations 55

Authors

Dayong Wang

G Govindaiah

Ruijie Liu

Vania De Arcangelis

Charles L Cox

Yang K Xiang

Affiliations

Soon will be listed here.

Abstract

Progressive decrease in neuronal function is an established feature of Alzheimer's disease (AD). Previous studies have shown that amyloid beta (Abeta) peptide induces acute increase in spontaneous synaptic activity accompanied by neurotoxicity, and Abeta induces excitotoxic neuronal death by increasing calcium influx mediated by hyperactive alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) receptors. An in vivo study has revealed subpopulations of hyperactive neurons near Abeta plaques in mutant amyloid precursor protein (APP)-transgenic animal model of Alzheimer's disease (AD) that can be normalized by an AMPA receptor antagonist. In the present study, we aim to determine whether soluble Abeta acutely induces hyperactivity of AMPA receptors by a mechanism involving beta(2) adrenergic receptor (beta(2)AR). We found that the soluble Abeta binds to beta(2)AR, and the extracellular N terminus of beta(2)AR is critical for the binding. The binding is required to induce G-protein/cAMP/protein kinase A (PKA) signaling, which controls PKA-dependent phosphorylation of GluR1 and beta(2)AR, and AMPA receptor-mediated excitatory postsynaptic currents (EPSCs). beta(2)AR and GluR1 also form a complex comprising postsynaptic density protein 95 (PSD95), PKA and its anchor AKAP150, and protein phosphotase 2A (PP2A). Both the third intracellular (i3) loop and C terminus of beta(2)AR are required for the beta(2)AR/AMPA receptor complex. Abeta acutely induces PKA phosphorylation of GluR1 in the complex without affecting the association between two receptors. The present study reveals that non-neurotransmitter Abeta has a binding capacity to beta(2)AR and induces PKA-dependent hyperactivity in AMPA receptors.

Citing Articles

Deciphering the Role of Adrenergic Receptors in Alzheimer's Disease: Paving the Way for Innovative Therapies.

Miliotou A, Kotsoni A, Zacharia L Biomolecules. 2025; 15(1).

PMID: 39858522 PMC: 11764010. DOI: 10.3390/biom15010128.

ExoY infection of pulmonary microvascular endothelial cells releases cyclic nucleotides into the extracellular compartment.

Stone M, Choi C, Dey N, Swain G, Stevens T, Sayner S Am J Physiol Lung Cell Mol Physiol. 2024; 327(5):L756-L768.

PMID: 39316682 PMC: 11560077. DOI: 10.1152/ajplung.00038.2024.

Neuroprotective actions of norepinephrine in neurological diseases.

Ghasemi M, Mehranfard N Pflugers Arch. 2024; 476(11):1703-1725.

PMID: 39136758 DOI: 10.1007/s00424-024-02999-w.

The duality of amyloid-β: its role in normal and Alzheimer's disease states.

Azargoonjahromi A Mol Brain. 2024; 17(1):44.

PMID: 39020435 PMC: 11256416. DOI: 10.1186/s13041-024-01118-1.

Association between Incidence of Prescriptions for Alzheimer's Disease and Beta-Adrenoceptor Antagonists: A Prescription Sequence Symmetry Analysis.

Alghamdi A, Bijlsma M, de Vos S, Schuiling-Veninga C, Bos J, Hak E Pharmaceuticals (Basel). 2023; 16(12).

PMID: 38139820 PMC: 10748070. DOI: 10.3390/ph16121694.

References

Beene D, Scott J . A-kinase anchoring proteins take shape. Curr Opin Cell Biol. 2007; 19(2):192-8. PMC: 3521038. DOI: 10.1016/j.ceb.2007.02.011. View

Tong L, Thornton P, Balazs R, Cotman C . Beta -amyloid-(1-42) impairs activity-dependent cAMP-response element-binding protein signaling in neurons at concentrations in which cell survival Is not compromised. J Biol Chem. 2001; 276(20):17301-6. DOI: 10.1074/jbc.M010450200. View

Johnson D, Akamine P, Radzio-Andzelm E, Madhusudan M, Taylor S . Dynamics of cAMP-dependent protein kinase. Chem Rev. 2001; 101(8):2243-70. DOI: 10.1021/cr000226k. View

Wang Y, De Arcangelis V, Gao X, Ramani B, Jung Y, Xiang Y . Norepinephrine- and epinephrine-induced distinct beta2-adrenoceptor signaling is dictated by GRK2 phosphorylation in cardiomyocytes. J Biol Chem. 2007; 283(4):1799-807. DOI: 10.1074/jbc.M705747200. View

Lesne S, Koh M, Kotilinek L, Kayed R, Glabe C, Yang A . A specific amyloid-beta protein assembly in the brain impairs memory. Nature. 2006; 440(7082):352-7. DOI: 10.1038/nature04533. View

Neubig R, Siderovski D . Regulators of G-protein signalling as new central nervous system drug targets. Nat Rev Drug Discov. 2002; 1(3):187-97. DOI: 10.1038/nrd747. View

Amatniek J, Hauser W, DelCastillo-Castaneda C, Jacobs D, Marder K, Bell K . Incidence and predictors of seizures in patients with Alzheimer's disease. Epilepsia. 2006; 47(5):867-72. DOI: 10.1111/j.1528-1167.2006.00554.x. View

Gainetdinov R, Premont R, Bohn L, Lefkowitz R, Caron M . Desensitization of G protein-coupled receptors and neuronal functions. Annu Rev Neurosci. 2004; 27:107-44. DOI: 10.1146/annurev.neuro.27.070203.144206. View

Hoogendijk W, Meynen G, Feenstra M, Eikelenboom P, Kamphorst W, Swaab D . [Increased activity of stress-regulating systems in Alzheimer disease]. Tijdschr Gerontol Geriatr. 2001; 32(1):17-23. View

10.

Hsieh H, Boehm J, Sato C, Iwatsubo T, Tomita T, Sisodia S . AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron. 2006; 52(5):831-43. PMC: 1850952. DOI: 10.1016/j.neuron.2006.10.035. View

11.

Echeverria V, Ducatenzeiler A, Chen C, Cuello A . Endogenous beta-amyloid peptide synthesis modulates cAMP response element-regulated gene expression in PC12 cells. Neuroscience. 2005; 135(4):1193-202. DOI: 10.1016/j.neuroscience.2005.06.057. View

12.

Francis P . Altered glutamate neurotransmission and behaviour in dementia: evidence from studies of memantine. Curr Mol Pharmacol. 2009; 2(1):77-82. DOI: 10.2174/1874467210902010077. View

13.

Ye C, Walsh D, Selkoe D, Hartley D . Amyloid beta-protein induced electrophysiological changes are dependent on aggregation state: N-methyl-D-aspartate (NMDA) versus non-NMDA receptor/channel activation. Neurosci Lett. 2004; 366(3):320-5. DOI: 10.1016/j.neulet.2004.05.060. View

14.

Liu R, Ramani B, Soto D, De Arcangelis V, Xiang Y . Agonist dose-dependent phosphorylation by protein kinase A and G protein-coupled receptor kinase regulates beta2 adrenoceptor coupling to G(i) proteins in cardiomyocytes. J Biol Chem. 2009; 284(47):32279-87. PMC: 2781641. DOI: 10.1074/jbc.M109.021428. View

15.

Banke T, Bowie D, Lee H, Huganir R, Schousboe A, Traynelis S . Control of GluR1 AMPA receptor function by cAMP-dependent protein kinase. J Neurosci. 2000; 20(1):89-102. PMC: 6774102. View

16.

Tao J, Wang H, Malbon C . Protein kinase A regulates AKAP250 (gravin) scaffold binding to the beta2-adrenergic receptor. EMBO J. 2003; 22(24):6419-29. PMC: 291823. DOI: 10.1093/emboj/cdg628. View

17.

Jacobsen J, Wu C, Redwine J, Comery T, Arias R, Bowlby M . Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 2006; 103(13):5161-6. PMC: 1405622. DOI: 10.1073/pnas.0600948103. View

18.

AbdAlla S, Lother H, El Missiry A, Langer A, Sergeev P, Faramawy Y . Angiotensin II AT2 receptor oligomers mediate G-protein dysfunction in an animal model of Alzheimer disease. J Biol Chem. 2008; 284(10):6554-65. DOI: 10.1074/jbc.M807746200. View

19.

Pettit D, Shao Z, Yakel J . beta-Amyloid(1-42) peptide directly modulates nicotinic receptors in the rat hippocampal slice. J Neurosci. 2001; 21(1):RC120. PMC: 6762461. View

20.

Rosenberg P, Mielke M, Tschanz J, Cook L, Corcoran C, Hayden K . Effects of cardiovascular medications on rate of functional decline in Alzheimer disease. Am J Geriatr Psychiatry. 2008; 16(11):883-92. PMC: 2676234. DOI: 10.1097/JGP.0b013e318181276a. View